Characteristic | Total n (%) | Blood culture positive for MTB, n (%) | Blood culture negative for MTB, n (%) | Bivariate relative risk [95% confidence interval], p-value |
---|---|---|---|---|
Total | n = 130 | n = 41 | n = 89 | |
Sex: | ||||
Male | 73 (56) | 22 (54) | 51 (57) | 1.16 [0.55-2.4] p = 0.70 |
Female | 57 (44) | 19 (46) | 38 (43) | referent |
Age range (years): | ||||
0-14 | 8 (6) | 1 (2) | 7 (8) | 0.42 [0.05-3.7] p = 0.43 |
15-25 | 15 (11) | 7 (17) | 8 (9) | 2.57 [0.81-8.2] p = 0.11 |
26-35 | 67 (52) | 17 (41) | 50 (56) | referent |
36-45 | 28 (22) | 11 (27) | 17 (19) | 1.9 [0.75-4.9] p = 0.18 |
> 45 | 12 (9) | 5 (12) | 7 (8) | 2.1 [0.59-7.5] p = 0.25 |
Prior history of TB treatment | ||||
Yes | 42 (32) | 15 (37) | 27 (30) | 1.33 [0.61-2.9] p = 0.48 |
No | 88 (68) | 26 (63) | 62 (70) | referent |
Currently on first-line TB treatment | ||||
Yes | 89 (69) | 28 (68) | 61 (69) | 0.99 [0.45-2.2] p = 0.98 |
No | 41 (31) | 13 (32) | 28 (31) | referent |
Duration of TB treatment for patients on treatment (median weeks) [IQR] | 8 [4.0-20.0] | 10 [4.0-24] | 8 [5.5-13.5] | p = 0.76 |
Clinical features extrapulmonary TB | ||||
Yes | 45 (35) | 19 (46) | 26 (29) | 2.10 [0.97-4.5] p = 0.06 |
No | 85 (65) | 22 (54) | 63 (71) | referent |
HIV status: | ||||
Positive | 114 (88) | 34 (83) | 80 (90) | p > 0.99 |
Negative | 1 (1) | 0 (0) | 1 (1) | referent |
Unknown | 15 (11) | 7 (17) | 8 (9) | p > 0.99 |
CD4 counta (median cells/mm3) [IQR] | 100b [28-190] | 92 [81-174] | 104 [21-222] | p = 0.82 |
CD4 count cells/mm3 | ||||
0-100 | 32 (51) | 24 (50) | 8 (54) | 1.92 [0.35-10.5] p = 0.45 |
101-200 | 17 (27) | 12 (25) | 5 (33) | 2.73 [0.44-17.1] p = 0.29 |
> 200 | 14 (22) | 12 (25) | 2 (13) | referent |
Receiving antiretroviral therapyc | ||||
Yes | 53 (47) | 9 (26) | 44 (55) | 0.29 [0.12-0.71] p = 0.005 |
No | 61 (53) | 25 (72) | 36 (45) | referent |
Duration of antiretroviral therapy(median weeks) [IQR] | 15 [4-31] | 16 [7-32] | 15 [5-30] | p = 0.92 |